The global market is expected to enjoy a valuation of US$ 123.2 Billion by the end of the year 2023, and further expand at a CAGR of 5.2% to reach a valuation of ~US$ 205.3 Billion by the year 2033. According to the recent study by Future Market Insights, degenerative diseases are leading the market with an expected share of about 31.7% in the year 2023, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 117.6 Billion |
| Market Value 2023 | US$ 123.2 Billion |
| Market Value 2033 | US$ 205.3 Billion |
| CAGR 2023-2033 | 5.2% |
| Market Share of Top 5 Countries (2022) | 54.8% |
| Key Market Players List | Abbvie Inc, Alkermes Plc, Allergan Plc, AstraZeneca Plc, BIAL Group, Bristol-myers Squibb, Eisai Co, Ltd., Endo Pharmaceuticals, Eli Lilly and Co, and F. Hoffmann-La Roche Ltd. |
The CNS or central nervous system is the coordinating or control mechanism of the animal body, including humans. Degeneration of nervous tissues or disorders in the brain and spinal cords is the prominent reason for several types of neurodegenerative diseases.
New research activities conducted in the sphere of mental health and psychiatric disorders have increased the demand for treatment and therapeutic opportunities available in the CNS treatment and therapy market.
The growth of CNS therapeutics for the soaring cases of mental illness and central nervous system disorders associated with faulty lifestyle is providing the necessary impetus for the establishment and growth of the CNS treatment and therapy market across the geographical regions.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for CNS treatment and therapy was around 57.8% of the overall ~US$ 203.6 Billion of the global antibody therapy market in 2022.
The sale of CNS treatment and therapy expanded at a CAGR of 4.66% from 2017 to 2022.
Over the years, increased incidents of psychological disorders and nervous breakdown have emerged as a major concern across the globe. By the applications of several types of chemical formulations such as anaesthetic anti-Parkinson's drugs and antiepileptic drugs, the CNS treatment and therapy has relieved many patients across the globe, creating a huge market.
According to Parkinson's Foundation, the global count of patients suffering from Parkinson's disease is estimated to be 10 million in 2022. The diagnosis report for other nervous system disorder diseases have also increased significantly in the recent past and is estimated to reach 82 million by 2030. This situation creates ample of opportunity for pharmaceutical companies to generate revenues by delivering treatment and therapeutic options for the patients.
Increased government funding to accelerate the clinical development of newly discovered drugs is expected to fuel the rapid growth of the central nervous system therapeutics market during the forecast period. The introduction of new therapies like serotonin and norepinephrine reuptake inhibitors (SNRIs) have acquired huge traction within a short period of time.
Thus, owing to the aforementioned factors, the global CNS treatment and therapy market is projected to expand at a CAGR of 5.2% during the forecast period between 2023 and 2033.
H1-H2 Update
| Market Statistics | Details |
|---|---|
| Jan-Jun (H1), 2021 (A) | 3.99% |
| Jul-Dec (H2), 2021 (A) | 5.13% |
| Jan-Jun (H1),2022 Projected (P) | 3.70% |
| Jan-Jun (H1),2022 Outlook (O) | 4.00% |
| Jul-Dec (H2), 2022 Outlook (O) | 5.26% |
| Jul-Dec (H2), 2022 Projected (P) | 5.03% |
| Jan-Jun (H1), 2023 Projected (P) | 3.87% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 30↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 1↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 22↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 12↑ |
According to the Alzheimer’s Association, the number of patients suffering from Alzheimer’s is predicted to reach nearly 13 billion in the USA alone by 2050. Alzheimer’s, along with other neurological disorders in the ageing population, is predicted to keep demand for CNS treatment and therapy services high in the US market and other regions as well.
New product launches by adopting upgraded techniques are the prospective growth strategy that is adopted by major market players operating in the central nervous system therapeutics market. For instance, the Corbus Pharmaceutical Inc. of Japan started the commercialization of the Lenabasum drug in Japan by entering into an agreement with Kaken pharmaceutical company in 2019.
The rising cases of mental health disorders among the general population has provided the necessary impetus for the central and regional governments to make necessary provisions for the treatment of CNS disorders. Canada released its first national strategy for controlling dementia by spending US$ 200 Million though the Canadian Institute of Health Research in 2019.
The global CNS therapeutics is categorized based on the class of drugs used for the treatment of central nervous system disorders. Immunomodulators and interferon are analysed to be constantly driving the central nervous treatment drug market by the innovation of therapeutic molecules implemented for the treatment of neurological diseases symptoms.
Principal Consultant
Strong guidelines for the approval of newly developed drug Formulations before introduction into the market hamper the competitive edge of pharmaceutical companies investing heavily in research and development. Failure rates of various newly introduced drugs for nervous system therapeutics is also higher, which poses a major challenge for the growth of the market.
The wide availability of generic drugs is also anticipated to limit the growth of private market players supplying neurological disorder drugs, anaesthetics, anti-Parkinson drugs and its other variants. Agreement with government organizations to supply neurological disease prevention products can be established to incur higher profit from the CNS treatment and therapy services.
The introduction of novel drug delivery systems in the past decade have faced the issue of its acceptance in healthcare sectors of all regions.
Dissemination of proper information to the CNS treatment and therapy centres is the underlying challenge that may hinder the market players from realizing their full potential.
| Country | USA |
|---|---|
| 2023 | 31.70% |
| 2033 | 31.20% |
| BPS Analysis | -52 |
| Country | Germany |
|---|---|
| 2023 | 6.70% |
| 2033 | 7.20% |
| BPS Analysis | 46 |
| Country | UK |
|---|---|
| 2023 | 5.70% |
| 2033 | 5.70% |
| BPS Analysis | -3 |
| Country | Canada |
|---|---|
| 2023 | 5.70% |
| 2033 | 5.70% |
| BPS Analysis | 7 |
| Country | China |
|---|---|
| 2023 | 5.60% |
| 2033 | 6.20% |
| BPS Analysis | 59 |
The USA is set to hold a total market share of about 31.7% in 2023.
The primary causes of these enormous market growth tendencies in the USA market includes rising percentage of the elderly population and the greatest level of healthcare spending. The demand within the global market is projected to rise as people become more aware of the neurodegenerative illnesses, autoimmune and inflammatory disorders, and their potential for treatment.
Germany is set to hold a market share of nearly 6.7% in the global CNS treatment and therapy market in 2023.
Given the intricacy of the condition and the scarcity of accessible controlled research, among the most sensitive issues in neuro-oncology is the treatment of primary CNS lymphoma. The European Association of Neuro-Oncology established a multidisciplinary task force in 2013 to develop evidence-based recommendations for immunocompetent adults with primary CNS lymphoma.
The recommendations cover topics such as the management of aged patients as well as features of care for surgery, systemic and intrathecal chemotherapy, intense chemotherapy with autologous stem-cell transplantation, radiation, and ophthalmic symptoms. The recommendations should support doctors in their day-to-day work and decision-making, act as a foundation for next neuro-oncology studies, and increase market value in Germany.
China contributes about 5.6% revenue share to the global market.
China has become a significant market for anesthetics anti-Parkinson medications as a result of modernizing its healthcare infrastructure. With the increasing development and manufacturing of novel biologics for CNS treatment, the market is set to advance, as Chinese manufacturing firms take more outsourcing activities.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Biologics are set to hold a share of around 68.7% in the global market, in 2023.
The blood brain barrier (BBB), which hinders attaining enough drug concentrations at sites of action, precludes many central nervous system (CNS) illnesses from being properly treated by systemically delivered medicines. Direct CNS delivery will probably play a bigger part in therapy as a result of the rising prevalence of neurodegenerative illnesses and the inability of most systemically delivered medicines to penetrate the blood-brain barrier.
This problem is solved by administering big chemicals, cells, viral vectors, oligonucleotides, and other innovative therapeutics directly to the CNS through the subarachnoid space, ventricular system, or parenchyma.
Antidepressant segment holds about one-third value share within the global market.
CNS depressants are prescribed to treat seizures, anxiety, panic attacks, and sleeplessness. They can also be administered before surgery to calm nerves and relax. Sedatives, tranquillizers, and hypnotics are medications that depress the central nervous system (CNS). These medications can reduce brain activity, making them effective for treating anxiety, panic attacks, severe stress reactions, and sleep difficulties.
Degenerative diseases are set to hold a share of around 31.7% in the global market, in 2023.
Millions of people worldwide are affected by neurodegenerative disorders. The two most prevalent neurodegenerative illnesses are Alzheimer's disease and Parkinson's disease. According to an estimate from the Alzheimer's Disease Association, 6.2 million people in the USA had Alzheimer's disease by 2022.
Hospital pharmacies segment is set to hold a share of around 48.6% in the global market, in 2023.
Increasing prevalence of neurodegenerative disorders, as well as the rising patient inflow into hospital settings are factors propelling institutional sales within the hospital pharmacies. With appropriate prescription and treatment regime, this segment is set to expand over the forecast period, owed to greater patient compliance, as well as availability of medications in-house.
The various regional players operating in CNS therapeutics market adopt acquiring government funding to support novel research activities in the field of nervous system disorder diseases.
Global players with higher valuation incur higher spending on clinical trials of different products such as anesthetic anti-Parkinson drugs for launching it in market. Strategic collaborations is the major strategy adopted by such market players to expand their consumer base.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the CNS treatment and therapy space, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Drug, Drug Class, Disease, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is estimated to acquire US$ 123.2 billion in 2023.
Nonselective, multipotent therapies appear to be more effective, thus propelling market growth.
The United States accounts for 31% of the market in 2023.
Germany holds a market share of nearly 6.7% in the market in 2023.
The scarcity of accessible controlled research, among the most sensitive issues is driving growth.
1. Market- Executive Summary | CNS Treatment and Therapy Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion and Exclusion
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Product USPs
4.3. Promotional Strategies, By Key Players
4.4. Regulatory Scenario
4.5. Technology Assessment
4.6. PESTEL Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Industry Market Outlook
5.1.3. Global Antibody Therapy Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growing Advancements in Drug Discovery Techniques
5.2.2. Rising Awareness on Neuropsychiatric Disorders
5.2.3. Increasing Research and Development Activities on Psychedelic Use for Mental Health
5.2.4. Rising Number of Neuroscience Drug Manufacturers
5.2.5. Rising Incidence of Psychiatric Disorders
5.2.6. Introduction of Novel Drug Delivery Systems
5.2.7. Increasing Initiatives by Government
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Drug
6.1.2. Revenue By Drug Class
6.1.3. Revenue By Disease
6.1.4. Revenue By Distribution Channel
6.1.5. Revenue By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Drug, 2017 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug, 2023 to 2033
8.3.1. Biologics
8.3.2. Non Biologics
8.4. Market Attractiveness Analysis By Drug
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
9.3.1. Antidepressant
9.3.2. Analgesics
9.3.3. Immunomodulators
9.3.4. Interferons
9.3.5. Decarboxylase Inhibitors
9.3.6. Others
9.4. Market Attractiveness Analysis By Drug Class
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Disease, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Disease, 2023 to 2033
10.3.1. Neurovascular Disease
10.3.2. Degenerative Disease
10.3.3. Infectious Disease
10.3.4. Mental Health
10.3.5. Others
10.4. Market Attractiveness Analysis By Disease
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis by Region, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East & Africa(MEA)
12.4. Market Attractiveness Analysis by Region
13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. US
13.3.1.2. Canada
13.3.2. By Drug
13.3.3. By Drug Class
13.3.4. By Disease
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug
13.4.3. By Drug Class
13.4.4. By Disease
13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. USA Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Drug
13.8.1.2.2. By Drug Class
13.8.1.2.3. By Disease
13.8.1.2.4. By Distribution Channel
13.8.2. Canada Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Drug
13.8.2.2.2. By Drug Class
13.8.2.2.3. By Disease
13.8.2.2.4. By Distribution Channel
14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug
14.3.3. By Drug Class
14.3.4. By Disease
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug
14.4.3. By Drug Class
14.4.4. By Disease
14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Brazil Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Drug
14.8.1.2.2. By Drug Class
14.8.1.2.3. By Disease
14.8.1.2.4. By Distribution Channel
14.8.2. Mexico Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Drug
14.8.2.2.2. By Drug Class
14.8.2.2.3. By Disease
14.8.2.2.4. By Distribution Channel
14.8.3. Argentina Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Drug
14.8.3.2.2. By Drug Class
14.8.3.2.3. By Disease
14.8.3.2.4. By Distribution Channel
15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. United Kingdom
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Drug
15.3.3. By Drug Class
15.3.4. By Disease
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug
15.4.3. By Drug Class
15.4.4. By Disease
15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Drug
15.8.1.2.2. By Drug Class
15.8.1.2.3. By Disease
15.8.1.2.4. By Distribution Channel
15.8.2. Italy Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Drug
15.8.2.2.2. By Drug Class
15.8.2.2.3. By Disease
15.8.2.2.4. By Distribution Channel
15.8.3. France Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Drug
15.8.3.2.2. By Drug Class
15.8.3.2.3. By Disease
15.8.3.2.4. By Distribution Channel
15.8.4. United Kingdom Market
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Drug
15.8.4.2.2. By Drug Class
15.8.4.2.3. By Disease
15.8.4.2.4. By Distribution Channel
15.8.5. Spain Market
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Drug
15.8.5.2.2. By Drug Class
15.8.5.2.3. By Disease
15.8.5.2.4. By Distribution Channel
15.8.6. BENELUX Market
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Drug
15.8.6.2.2. By Drug Class
15.8.6.2.3. By Disease
15.8.6.2.4. By Distribution Channel
15.8.7. Russia Market
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Drug
15.8.7.2.2. By Drug Class
15.8.7.2.3. By Disease
15.8.7.2.4. By Distribution Channel
16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Indonesia
16.3.1.4. Malaysia
16.3.1.5. Rest of South Asia
16.3.2. By Drug
16.3.3. By Drug Class
16.3.4. By Disease
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug
16.4.3. By Drug Class
16.4.4. By Disease
16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug
16.8.1.2.2. By Drug Class
16.8.1.2.3. By Disease
16.8.1.2.4. By Distribution Channel
16.8.2. Thailand Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug
16.8.2.2.2. By Drug Class
16.8.2.2.3. By Disease
16.8.2.2.4. By Distribution Channel
16.8.3. Indonesia Market
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug
16.8.3.2.2. By Drug Class
16.8.3.2.3. By Disease
16.8.3.2.4. By Distribution Channel
16.8.4. Malaysia Market
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Drug
16.8.4.2.2. By Drug Class
16.8.4.2.3. By Disease
16.8.4.2.4. By Distribution Channel
17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug
17.4.3. By Drug Class
17.4.4. By Disease
17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug
17.8.1.2.2. By Drug Class
17.8.1.2.3. By Disease
17.8.1.2.4. By Distribution Channel
17.8.2. Japan Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug
17.8.2.2.2. By Drug Class
17.8.2.2.3. By Disease
17.8.2.2.4. By Distribution Channel
17.8.3. South Korea Market
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Drug
17.8.3.2.2. By Drug Class
17.8.3.2.3. By Disease
17.8.3.2.4. By Distribution Channel
18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Drug
18.3.3. By Drug Class
18.3.4. By Disease
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug
18.4.3. By Drug Class
18.4.4. By Disease
18.4.5. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Drug
18.8.1.2.2. By Drug Class
18.8.1.2.3. By Disease
18.8.1.2.4. By Distribution Channel
18.8.2. New Zealand Market
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Drug
18.8.2.2.2. By Drug Class
18.8.2.2.3. By Disease
18.8.2.2.4. By Distribution Channel
19. Middle East and Africa Market Analysis 2017 to 2022and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Drug
19.3.3. By Drug Class
19.3.4. By Disease
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug
19.4.3. By Drug Class
19.4.4. By Disease
19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Drug
19.8.1.2.2. By Drug Class
19.8.1.2.3. By Disease
19.8.1.2.4. By Distribution Channel
19.8.2. Türkiye Market
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Drug
19.8.2.2.2. By Drug Class
19.8.2.2.3. By Disease
19.8.2.2.4. By Distribution Channel
19.8.3. South Africa Market
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Drug
19.8.3.2.2. By Drug Class
19.8.3.2.3. By Disease
19.8.3.2.4. By Distribution Channel
19.8.4. North Africa Market
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Drug
19.8.4.2.2. By Drug Class
19.8.4.2.3. By Disease
19.8.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Concentration
20.3. Market Share Analysis of Top Players
20.4. Market Presence Analysis
20.4.1. Regional footprint of Players
20.4.2. Product footprint of Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Deep Dive
21.2.1. AbbVie Inc.
21.2.1.1. Overview
21.2.1.2. Key Financials
21.2.1.3. Sales Footprint
21.2.1.4. SWOT Analysis
21.2.1.5. Strategy Overview
21.2.1.5.1. Marketing Strategy
21.2.1.5.2. Product Strategy
21.2.1.5.3. Channel Strategy
21.2.2. Alkermes Plc
21.2.2.1. Overview
21.2.2.2. Key Financials
21.2.2.3. Sales Footprint
21.2.2.4. SWOT Analysis
21.2.2.5. Strategy Overview
21.2.2.5.1. Marketing Strategy
21.2.2.5.2. Product Strategy
21.2.2.5.3. Channel Strategy
21.2.3. Allergan Plc
21.2.3.1. Overview
21.2.3.2. Key Financials
21.2.3.3. Sales Footprint
21.2.3.4. SWOT Analysis
21.2.3.5. Strategy Overview
21.2.3.5.1. Marketing Strategy
21.2.3.5.2. Product Strategy
21.2.3.5.3. Channel Strategy
21.2.4. AstraZeneca Plc
21.2.4.1. Overview
21.2.4.2. Key Financials
21.2.4.3. Sales Footprint
21.2.4.4. SWOT Analysis
21.2.4.5. Strategy Overview
21.2.4.5.1. Marketing Strategy
21.2.4.5.2. Product Strategy
21.2.4.5.3. Channel Strategy
21.2.5. BIAL Group
21.2.5.1. Overview
21.2.5.2. Key Financials
21.2.5.3. Sales Footprint
21.2.5.4. SWOT Analysis
21.2.5.5. Strategy Overview
21.2.5.5.1. Marketing Strategy
21.2.5.5.2. Product Strategy
21.2.5.5.3. Channel Strategy
21.2.6. Bristol-myers Squibb
21.2.6.1. Overview
21.2.6.2. Key Financials
21.2.6.3. Sales Footprint
21.2.6.4. SWOT Analysis
21.2.6.5. Strategy Overview
21.2.6.5.1. Marketing Strategy
21.2.6.5.2. Product Strategy
21.2.6.5.3. Channel Strategy
21.2.7. Eisai Co, Ltd.
21.2.7.1. Overview
21.2.7.2. Key Financials
21.2.7.3. Sales Footprint
21.2.7.4. SWOT Analysis
21.2.7.5. Strategy Overview
21.2.7.5.1. Marketing Strategy
21.2.7.5.2. Product Strategy
21.2.7.5.3. Channel Strategy
21.2.8. Endo Pharmaceuticals
21.2.8.1. Overview
21.2.8.2. Key Financials
21.2.8.3. Sales Footprint
21.2.8.4. SWOT Analysis
21.2.8.5. Strategy Overview
21.2.8.5.1. Marketing Strategy
21.2.8.5.2. Product Strategy
21.2.8.5.3. Channel Strategy
21.2.9. Eli Lilly and Co
21.2.9.1. Overview
21.2.9.2. Key Financials
21.2.9.3. Sales Footprint
21.2.9.4. SWOT Analysis
21.2.9.5. Strategy Overview
21.2.9.5.1. Marketing Strategy
21.2.9.5.2. Product Strategy
21.2.9.5.3. Channel Strategy
21.2.10. F. Hoffmann-La Roche Ltd.
21.2.10.1. Overview
21.2.10.2. Key Financials
21.2.10.3. Sales Footprint
21.2.10.4. SWOT Analysis
21.2.10.5. Strategy Overview
21.2.10.5.1. Marketing Strategy
21.2.10.5.2. Product Strategy
21.2.10.5.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
CNS Treatment and Therapy Market
